Comparison 1. A. Anti‐pseudomonas penicillins: piperacillin‐tazobactam vs ticarcillin‐clavulanate.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Clinical resolution of the infection | 1 | 63 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [0.59, 2.29] |